IL320663A - Treatment of immune thrombocytopenia - Google Patents

Treatment of immune thrombocytopenia

Info

Publication number
IL320663A
IL320663A IL320663A IL32066325A IL320663A IL 320663 A IL320663 A IL 320663A IL 320663 A IL320663 A IL 320663A IL 32066325 A IL32066325 A IL 32066325A IL 320663 A IL320663 A IL 320663A
Authority
IL
Israel
Prior art keywords
treatment
immune thrombocytopenia
thrombocytopenia
immune
Prior art date
Application number
IL320663A
Other languages
Hebrew (he)
Inventor
Vladimir Bezlyak
Tomasz Lawniczek
Emerenziana Marturano
Miona Stankovic
Patrick Urban
Palau Alejandro Javier Allepuz
Original Assignee
Novartis Ag
Vladimir Bezlyak
Tomasz Lawniczek
Emerenziana Marturano
Miona Stankovic
Patrick Urban
Palau Alejandro Javier Allepuz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Vladimir Bezlyak, Tomasz Lawniczek, Emerenziana Marturano, Miona Stankovic, Patrick Urban, Palau Alejandro Javier Allepuz filed Critical Novartis Ag
Publication of IL320663A publication Critical patent/IL320663A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL320663A 2022-11-16 2025-05-04 Treatment of immune thrombocytopenia IL320663A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263384049P 2022-11-16 2022-11-16
US202363481841P 2023-01-27 2023-01-27
PCT/IB2023/061465 WO2024105549A1 (en) 2022-11-16 2023-11-14 Treatment of immune thrombocytopenia

Publications (1)

Publication Number Publication Date
IL320663A true IL320663A (en) 2025-07-01

Family

ID=88839111

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320663A IL320663A (en) 2022-11-16 2025-05-04 Treatment of immune thrombocytopenia

Country Status (7)

Country Link
EP (1) EP4619026A1 (en)
JP (1) JP2025537796A (en)
KR (1) KR20250108117A (en)
CN (1) CN120265311A (en)
IL (1) IL320663A (en)
TW (1) TW202421196A (en)
WO (1) WO2024105549A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026122561A2 (en) 2024-12-03 2026-06-11 Otsuka America Pharmaceutical, Inc. Methods of treating sjögren's disease

Also Published As

Publication number Publication date
JP2025537796A (en) 2025-11-20
WO2024105549A1 (en) 2024-05-23
EP4619026A1 (en) 2025-09-24
KR20250108117A (en) 2025-07-15
TW202421196A (en) 2024-06-01
CN120265311A (en) 2025-07-04

Similar Documents

Publication Publication Date Title
EP4525871A4 (en) Treatment of depression
IL315503A (en) Methods of treatment
IL320711A (en) Methods of treatment
GB2595513B (en) Treatment of infections
GB202201824D0 (en) Methods of treatment
CA3273323A1 (en) Treatment of immune thrombocytopenia
GB202201819D0 (en) Methods of treatment
GB202201825D0 (en) Methods of treatment
HUE068787T2 (en) Thermal treatment of components
GB202102257D0 (en) Treatment of shells
GB202315695D0 (en) TReatment of cariomyopathy
GB202212506D0 (en) Treatment of covid-19
GB202307686D0 (en) Treatment of conditions
GB202206348D0 (en) Treatment of limb spasticity
IL325944A (en) Treatment methods
GB202003803D0 (en) Treatment of limb spasticity
GB202101251D0 (en) Treatment of conditions
GB202118007D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
GB202118011D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment
GB202108245D0 (en) Methods of treatment
ZA202005856B (en) Treatment of infections
GB202502238D0 (en) Treatment of COVID-19
GB202413538D0 (en) Treatment of haematoglobinopathies